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The synthetic Vitamin A analog fenretinide is a promising chemotherapeutic agent. In the current paper, the role of PKC δ was
examined in fenretinide-induced apoptosis in lymphoid leukemia cells. Levels of proapoptotic cleaved PKC δ positively correlated
with drug sensitivity. Fenretinide promoted reactive oxygen species (ROS) generation. The antioxidant Vitamin C prevented
fenretinide-induced PKC δ cleavage and protected cells from fenretinide. Suppression of PKC δ expression by shRNA sensitized
cells to fenretinide-induced apoptosis possibly by a mechanism involving ROS production. A previous study demonstrated that
fenretinide promotes degradation of antiapoptotic MCL-1 in ALL cells via JNK. Now we have found that fenretinide-induced
MCL-1 degradation may involve PKC δ as cleavage of the kinase correlated with loss of MCL-1 even in cells when JNK was not
activated. These results suggest that PKC δ may play a complex role in fenretinide-induced apoptosis and may be targeted in
antileukemia strategies that utilize fenretinide.
1.Introduction
Fenretinide (N-4-(hydroxyphenyl)-retinamide; 4-HPR) is a
synthetic analog of Vitamin A that has shown promise as
both a chemotherapeutic and chemopreventive agent in
solid tumors and hematologic malignancies [1–6]. While
fenretinide binding to retinoic acid receptors (RARs) can
promote apoptosis in some cell types, the agent can induce
death in a RAR-independent manner [1]. RAR-independent
mechanisms of cell death likely involve the production
of reactive oxygen species (ROS) and the generation of
sphingolipid second messenger molecules [7–11]. While
there have been numerous studies on fenretinide in recent
years, the identiﬁcation of diverse potential mechanisms for
fenretinideantineoplasticactivitysuggeststhattheagentmay
function diﬀerently in diﬀerent cell types [1, 11]. Fenretinide
has been shown to activate JNK [6, 12], promote ROS
generation [8], activate endoplasmic reticulum (ER) stress
pathways [13, 14] as well as activate the intrinsic apoptotic
pathway with various BCL2 family members as targets [15–
17]. Recent studies have suggested that fenretinide may be
an eﬀective agent in the treatment of acute lymphoblastic
leukemia (ALL) since the drug eﬀectively kills ALL cell
lines but not nonmalignant lymphoid cell types [5]. A
recent study from the Reynolds group has demonstrated
that fenretinide can synergize with ABT-737 to eﬀectively
kill ALL cells [18]. ABT-737 is a small molecule inhibitor of
many antiapoptotic BCL2 family members (but not MCL-
1) that is currently in clinical trials for a variety of cancers
[19–21]. MCL-1 has been found to promote resistance
to ABT-737-induced apoptosis and suppression of MCL-1
promotes sensitivity to the drug [19–21]. Fenretinide was
found to promote MCL-1 degradation by a JNK-mediated
mechanism and thus has promise in overcoming MCL-
1 mediated chemoresistance in ALL and other leukemias
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Kim and colleagues have discovered that fenretinide can
promote apoptosis via ROS activation of JNK, p38, ERK,
and PKC though the potential PKC isoforms involved were
not identiﬁed [6]. The protein kinase C (PKC) family is
composed of at least 11 members with distinct functions and
tissue distributions [22–25]. PKC isoforms are divided into
three groups based on structural features: classical (cPKC),
novel (nPKC), and atypical (aPKC). The cPKCs include PKC
α and PKC β and require calcium and diacylglycerol (DAG)
for activation [23]. The nPKCs include PKC δ and PKC ε
and require DAG but not calcium for activation. The aPKCs
include PKC ζ and require neither DAG nor calcium for
activation. Both cPKC and nPKC members have been impli-
catedinhematopoieticmalignancies[24,25].Moreisknown
about PKC signaling in myeloid than in lymphoid cells. PKC
α has been linked to leukemogenesis in B-cell chronic lym-
phocytic leukemia (B-CLL) [26]. PKC α promotes chemore-
sistance in ALL and acute myeloid leukemia (AML) cell lines
[27, 28] and may be a negative prognostic factor in AML [29,
30]. PKC β may support B-CLL cells by CD5-mediated sig-
naling [31]. PKC ε has been implicated in hairy cell leukemia
as an activator of ERK and RAC1 [32]. The role of PKC δ
in leukemia is more complicated. Unlike PKC α,P K Cβ,a n d
PKC ε which generally regulate survival signaling pathways,
PKC δ is regarded as a stress kinase [23, 33–36]. Cells derived
fromPKCδ nullmiceareresistanttoapoptosisinresponseto
chemotherapy drug or irradiation [37]. The mechanism how
PKC δ supports apoptosis is complex. In response to a stress
challenge, tyrosine phosphorylation of PKC δ promotes its
translocation to the nucleus where it is cleaved by Caspase 3
[33–36]. The cleaved PKC δ is active and targets a number
of nuclear substrates that may be essential for the induction
of cell death including Lamin, DNA dependent Protein
Kinase(DNA-PK),andp53[33–36].CleavedPKCδ hasbeen
suggestedtotargetMCL-1fordegradation[38].Considering
that fenretinide promotes MCL-1 degradation in ALL cell
lines [18], the possibility arises that the fenretinide-induced
apoptosis may involve PKC δ. In the present study, we
examined PKC δ expression and cleavage and MCL-1
expression in response to fenretinide in three ALL cell lines
(REH, CCRF-CEM, and MOLT4) and in a Mixed Lineage
Leukemia (MLL) cell line (RS4;11). Fenretinide promoted
cleavage of PKC δ and suppression of MCL-1 in cell lines
sensitivetothedrug(RS4;11andCCRF-CEM)butnotincell
lines that were more resistant (REH and MOLT4). In CCRF-
CEM cells, fenretinide promoted translocation of JNK from
the cytosol to the nucleus. Consistent with the ﬁndings of
the Reynolds group [18], fenretinide likely promotes MCL-1
protein degradation since fenretinide did not inhibit MCL-
1 gene expression in three of the four leukemia lines and
the drug actually promoted gene expression in REH cells
(perhaps as part of an initial SOS response for these cells).
Fenretinide promoted ROS production in three of the four
cell lines. The antioxidant Vitamin C protected all cell lines
fromthedrugandsuppressedPKCδ cleavagesuggestingthat
themechanismbywhichfenretinidepromotesdeathinvolves
ROS and PKC δ. Suppression of PKC δ in CCRF-CEM cells
by shRNA sensitized the cells to fenretinide suggesting that
loss of the kinase may also be important in the drug’s mode
of action. Basal ROS production was increased in cells with
reduced PKC δ suggesting that the increase in sensitivity
to the drug may be due to enhanced ROS generation. The
ﬁndings in this study suggest that PKC δ plays an important
role in fenretinide-induced apoptosis in lymphoid leukemia
cell lines.
2.MaterialsandMethods
2.1. Cell Lines and Plasmid DNAs. HEK-293T cells were
obtained from the ATCC (Manassas, VA) and maintained
in DMEM supplemented with 10% fetal bovine serum at
37
◦Ci n5 %C O 2. REH, CCRF-CEM, MOLT4, and RS4;11
cells were obtained from the ATCC and maintained in
RPMI 1640 + 10% fetal bovine serum at 37
◦Ci n5 %C O 2.
A set of four shRNAs targeting PKC δ from the lentivi-
ral shRNA library of The RNAi Consortium (designated
TRCN0000010193, TRCN0000010194, TRCN0000010202,
andTRCN0000010203)wasobtainedfromOpenBiosystems
(Huntsville, AL). Lentiviral packaging plasmids MD2.G
(Addgene plasmid 12259) and psPAX2 (Addgene plasmid
12260) were constructed by the laboratory of Didier Trono
and obtained from Addgene (Cambridge, MA). A control
lentiviral transfer plasmid, pLKO.1 TRC control (Addgene
plasmid 10879), was constructed by the laboratory of David
Root [39] and obtained from Addgene.
2.2. Lentiviral Transduction of shRNA. Each TRC lentiviral
shRNA plasmid was transiently cotransfected in an equimo-
larmixwiththelentiviralpackagingplasmidsintoHEK293T
cells using Lipofectamine 2000 (Invitrogen, Carlsbad, CA) as
directed by the manufacturer. Lentiviral supernatants were
harvestedat48hoursposttransfectionﬁrstbycentrifugation
for ten minutes at room temperature at 800×g and then by
ﬁltration through 0.45μM surfactant-free cellulose acetate
to assure complete removal of producing cells. Polybrene
(Chemicon, Temecula, CA) was then added to a concentra-
tion of 8μg/mL, and the resulting virus stock was used at
once to spinoculate CCRF-CEM cells. CCRF-CEM cells were
resuspended at a concentration of 0.5 million cells per mL of
v i r u ss t o c k ,t r a n s f e r r e dt ot h ew e l l so fa1 2w e l lt i s s u ec u l t u r e
cluster, and centrifuged for 45 minutes at 30
◦C at 1300×g.
Aftertheadditionofonevolumeoffreshvirusstock,thecells
weresubjecttoasecondroundofcentrifugation,followedby
incubation at 37
◦Ci n5 %C O 2 for 60 minutes. The infected
cells were then washed twice with growth medium to remove
the polybrene and allowed to grow for two doubling times
(42–44hours),afterwhichtimetheyweresubjecttoselection
with 1.0μg/mL puromycin (InvivoGen, San Diego, CA).
Puromycin-resistant pools of infected cells were assessed for
PKC δ knockdown by Western analysis.
2.3. Analysis of ROS Generation. ROS generation assay
was performed as reported by Kang and colleagues [18].
Cells were pretreated with 0.4M Vitamin C for 2 hours
prior to treatment with either vehicle (0.1% DMSO) or
1μM fenretinide for 24 hours. Cells were centrifuged and
resuspended in warm (37
◦C) medium containing 10μM5 -
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(carboxy-H2DCFDA; Invitrogen) and incubated for 20 min-
utes at 37
◦C. Cells were then centrifuged and washed with
phosphate-buﬀered saline, and then analyzed on a Becton
DickinsonFACSCaliburﬂowcytometer(BDBiosciences,San
Jose, CA).
2.4. Analysis of Cell Death and Apoptosis by Annexin V
Staining. Cells were treated with varying doses of fenre-
tinide (Calbiochem, San Diego, CA) for 24 hours. Where
appropriate, cells were pretreated 2 hours with Vitamin C
(Sigma,St.Louis,MO),Caspase8inhibitor(Calbiochem),or
Caspase 9 inhibitor (Calbiochem) or 1 hour with Bryostatin-
1 (Calbiochem) prior to the addition of fenretinide. Cell
viability was measured by trypan blue dye exclusion and
apoptosis was evaluated using the Annexin V-FITC Apop-
tosis Detection Kit (MBL International, Woburn, MA). The
cells were washed twice with PBS and resuspended in 450μL
1X Annexin Binding Buﬀer. 5μL of Annexin V-FITC and
5μL of PI were added to each tube. The cells were mixed
gently and incubated for 5 minutes in the dark at room
temperature. Cells were analyzed on a Becton Dickinson
FACSCalibur ﬂow cytometer (BD Biosciences, San Jose, CA),
placingtheFITCsignalinFL1andthePIsignalinFL2.Intact
cells were gated in the FSC/SSC plot to exclude small debris.
Cells in the lower right quadrant of the FL1/FL2 dot plot
(labeled with Annexin V-FITC only) are considered to be in
earlyapoptosis,andcellsintheupperrightquadrant(labeled
with Annexin V-FITC and PI) are in late apoptosis/necrosis.
2.5. Western Analysis. Total protein (2 ×105 cell equivalents)
was subjected to SDS-PAGE using antibodies speciﬁc for the
analyzed proteins. Antibodies used were Caspase 3 (Santa
Cruz Biotechnology, Santa Cruz, CA), Caspase 8 (Santa
CruzBiotechnology),Caspase9(SantaCruzBiotechnology),
PARP (Santa Cruz Biotechnology), PKC α (Santa Cruz
Biotechnology), PKC βI (Santa Cruz Biotechnology), PKC
βII (Santa Cruz Biotechnology), PKC δ (Santa Cruz Biotech-
nology), PKC ε (Santa Cruz Biotechnology), p-JNK (Cell
Signaling, Danvers, MA), JNK (Cell Signaling), BCL2 (Dako,
Carpinteria, CA), BCL-XL (Santa Cruz Biotechnology),
MCL-1 (Santa Cruz Biotechnology), and Tubulin (Sigma).
2.6. Fluorescence Microscopy. Cells were suspended in RPMI
media and sedimented onto round poly-L-lysine coated
coverslips (Biocoat, BD Biosciences, Bedford, MA), using a
Sorval RC-6 high speed centrifuge (Thermo Fischer, Pitts-
burgh, PA), with an HB-6 swinging bucket rotor and custom
madetubeinsertsat1200×Gfor15minutes.Coverslipswere
ﬁxed in −20
◦C methanol, and processed for immunoﬂu-
orescence. Cells were immunolabeled with a monoclonal
antibody against α-tubulin (Sigma, St. Louis MO), and a
polyclonal antibody against PKC-δ. Secondary antibodies
goat antimouse Alexa ﬂuor 488 and goat antirabbit Alexa
ﬂuor 594, and counter stained with DAPI. Cells were imaged
with a Leica DM RXA-2 microscope (Leica Microsystems,
Bannockburn,IL),withﬂuorescenceopticsusingaLeica63×
1.4NA Apochromat CS objective and a Hamamatsu ORCA-
ER cooled CCD camera (Hamamatsu, E. Bridgewater, NJ).
I m a g e sw e r ec o l l e c t e da saZs e r i e so f0 . 5 μM, and were
deconvolved by constrained iterative, blind deconvolution
using Simple PCI imaging software (Hamamatsu Imaging,
Sewickley,PA).Zseriesarepresentedasamaximalprojection
and ﬁnal images were cropped and adjusted for contrast in
Photoshop (Adobe, Mountain View, CA).
2.7. Gene Expression Analysis. Total RNA was extracted
from cells using TriReagent (Sigma) as directed by the
manufacturer. To ensure complete removal of trace genomic
DNA or other factors that could interfere with downstream
enzymatic processes, all RNA samples were subjected to ﬁnal
puriﬁcation using RNeasy Mini Columns (Qiagen, Valencia,
CA)withon-columntreatmentbyDNAseIasdirectedbythe
manufacturer. cDNA was prepared from 1.0μgo ft o t a lR N A
per 20μL mix containing 0.07μg/μL random-sequence hex-
amer primers, 1mM dNTPs, 5mM DTT, 0.2u/μLS u p e r A s i n
RNAse inhibitor (Ambion, Austin, TX), and 10u/μLS u p e r -
Script III reverse transcriptase (Invitrogen). RNA and
primers were denatured 5 minutes at 70
◦C and then chilled
on ice. All components except enzyme were added and the
mixture was incubated at room temperature for 2 minutes
to allow nucleic acids to anneal. After addition of reverse
transcriptase, the mixture was incubated for ten minutes at
25
◦C, then one hour at 50
◦C, followed by heat-inactivation
of the enzyme for 15 minutes at 72
◦C. All cDNAs were stored
at −80
◦C when not in use. To verify the complete removal of
any residual genomic material in the real-time PCR assays,
we incubated in parallel 1.0μg of total RNA per 20μLo fa
mix containing all components except reverse transcriptase.
Real-time PCR was carried out using an ABI Model 7500
SequenceDetectionSystem(AppliedBiosystems,FosterCity,
CA). Duplicate 25μL reactions containing the cDNA equiva-
lentof50pgtotalRNAwererunandrepeatediftheCtvalues
were more than 0.25 cycles apart. As primers and probes we
usedthefollowingTaqManGeneExpression Assays(Applied
Biosystems) as directed by the manufacturer: MCL1 assay ID
Hs00172036 m1, BCL2 assay ID Hs00236808 s1, B2M assay
ID Hs99999907 m1, and 18SrRNA Hs99999901 s1. We used
18S rRNA to normalize gene expression. To calculate the
relative abundance (RA) of each transcript of interest relative
to that of 18S, the following formula was employed: RA =
1000000×2[−ΔCt] ,whereΔCtisthemeanCtofthetranscript
of interest minus the mean Ct of the transcript for 18S.
2.8. Statistics. Statistical analysis was performed using stan-
dardt-testanalysiswithSigmaStatcomputersoftware(SSPS,
Chicago, IL). Results are expressed as means ± SD of 3
separate replicate experiments. Values of P<. 05 were
considered signiﬁcant.
3. Results
3.1. Fenretinide Promotes Cell Death in Leukemia Cell Lines
by a Mechanism Involving ROS. Sensitivity to fenretinide
was investigated in the T-ALL derived cell lines CCRF-
CEM and MOLT4 cells, in the pre-B ALL derived cell line
REH, and in the MLL derived cell line RS4;11. Cells were4 Journal of Signal Transduction
treated with vehicle (0.1% DMSO) or with 1μM, 5μM, or
10μM fenretinide for 24 hours and programmed cell death
was assessed by Annexin V staining using FACSCAN. As
shown in Figure 1, CCRF-CEM and RS4;11 cells were the
most sensitive to fenretinide. At 1μM fenretinide, >30% of
CCRF-CEM and RS4;11 cells were positive for Annexin V
staining while higher doses of the drug induce apoptosis
in the majority of cells from both cell lines (i.e., >80% at
5μMa n d>89% at 10μM; Figure 1). Compared to CCRF-
CEM and RS4;11 cells, MOLT 4 cells were more resistant to
fenretinide. As shown in Figure 1, REH cells displayed the
greatest resistance to fenretinide-induced apoptosis.
SinceRS4;11cellsarep53+andCCRF-CEMcellscontain
mutant p53, p53 does not appear to be required for
fenretinide-inducedcelldeath.Thisﬁndingisconsistentwith
published reports indicating that fenretinide acts to kill cells
via a p53 independent mechanism [1]. Fenretinide has been
shown to promote cell death via a ROS-mediated mecha-
nism. As shown in Figure 2, treatment of cells with 1μM
fenretinide for 24 hours promoted potent ROS generation
in RS4;11 cells (i.e., >3.8 fold increase, P<. 001) and
CCRF-CEM cells (i.e., ∼9 fold increase, P<. 001). MOLT4
cells treated similarly with fenretinide exhibited a slight but
statistically signiﬁcant increase in ROS produced (i.e., 45%,
P<. 003). Treatment of REH cells with 1μM fenretinide for
24 hours had no eﬀect on ROS generation. However, REH
cells treated with 5μMd r u gd i ds h o wa>-4 fold increase in
ROS production (P<. 002) after 24 hours (data not shown).
These results suggest that there is a positive correlation
between ROS generation and sensitivity to fenretinide.
If ROS generation is critical to fenretinide-induced
apoptosis, it would be expected that an antioxidant such
as Vitamin C (L-abscorbic acid) would protect cells from
the cytotoxic eﬀects of the drug. REH, MOLT4, RS4;11, and
CCRF-CEM cells were treated with vehicle (0.2% DMSO),
0.4M Vitamin C, 5μM fenretinide, or a combination of
Vitamin C and drug at the speciﬁed concentrations for
24 hours. Induction of apoptosis was then measured by
FACSCAN analysis of cells to identify Annexin V positive
cells. Vitamin C alone had no eﬀe c to nR S 4 ; 1 1o rM O L T 4
cells but did have a slight eﬀect on the other two cells lines
(Figure 3). Vitamin C promoted an increase of apoptotic
CCRF-CEM cells compared to cells treated with vehicle (i.e.,
9.4% versus 5.7%, resp.; P<. 002). In REH cells, Vitamin C
alone reduced the population of apoptotic CCRF-CEM cells
comparedtocellstreatedwithvehicle(i.e.,5.3%versus3.2%,
resp.; P<. 002). As shown in Figure 3, Vitamin C protected
all four cell lines from fenretinide-induced apoptosis. This
result strongly suggests that ROS production is a key element
in the mechanism by which fenretinide kills leukemia cells.
3.2.FenretinidePromotesCaspaseActivation. Ithasbeenpre-
viously established that fenretinide can promote apoptosis
in leukemia cell lines such as CCRF-CEM by induction of
mitochondrial-mediated oxidative stress [7, 8, 18]. However,
a recent study has suggested that Caspase activity is not
required for fenretinide-induced cell death in lymphoid
leukemia cell lines [18]. Caspase activation in response to
fenretinide was determined in the lymphoid leukemia cell
0
20
40
60
80
100
A
n
n
e
x
i
n
V
+
(
%
)
Vehicle 1 μM 4-HPR 5 μM 4-HPR 10 μM 4-HPR
REH
MOLT4
RS4;11
CCRF CEM
∗
∗
∗∗
∗
∗
∗∗
∗
∗∗∗
Figure 1: Fenretinide promotes apoptosis in leukemia cell lines.
Apoptosis of human leukemia derived REH, MOLT4, RS4;11 and
CCRF-CEM cells treated with vehicle (0.1% DMSO) or fenretinide
(4-HPR at 1μM, 5μMo r1 0μMd o s e )f o r2 4h o u r sw a se x a m i n e d
using FACSCAN analysis of Annexin V stained cells. Error bars
represent the mean ± S.D. from three separate experiments.
Statistically signiﬁcant diﬀerences from cell viability in untreated
cells (standard t-test; P<. 05) are marked by “∗”.
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Figure 2: Fenretinide promotes ROS generation in leukemia cell
lines.GenerationofROSinhumanleukemiaderivedREH,MOLT4,
RS4;11 and CCRF-CEM cells treated with vehicle (0.1% DMSO)
or fenretinide (1μM 4-HPR) for 24 hours was examined using
FACSCAN analysis of Carboxy-H2DCFDA stained cells. Error
bars represent the mean ± S.D. from three separate experiments.
Statistically signiﬁcant diﬀerences from cell viability in untreated
cells (standard t-test; P<. 05) are marked by “∗”.Journal of Signal Transduction 5
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Figure 3: The antioxidant Vitamin C protects leukemia cell lines
from fenretinide-induced apoptosis. Apoptosis of human leukemia
derived REH, MOLT4, RS4;11 and CCRF-CEM cells treated with
vehicle (0.2% DMSO) or fenretinide (10μM 4-HPR) for 24 hours
was examined using FACSCAN analysis of Annexin V stained cells.
Where appropriate, cells were pretreated for 2 hours with 0.4M
Vitamin C (Vit C). Error bars represent the mean ± S.D. from three
separate experiments. Statistically signiﬁcant diﬀerences from cell
viability in untreated cells (standard t-test; P<. 05) are marked by
“∗”.
lines. Cells were treated with varying doses of drug for
24 hours and Caspase activation was observed by Western
analysis of PARP cleavage. As shown in Figure 4, PARP
cleavage was observed in RS4;11 and CCRF-CEM cells
treated with 1μM fenretinide while complete PARP cleavage
is seen with 5μM of the drug. REH cells and MOLT4
cells, which are relatively more resistant to fenretinide-
induced cell death compared to RS4;11 and CCRF-CEM
cells, displayed less PARP cleavage in response to fenretinide.
In fact, PARP is only partially cleaved in REH cells even
when treated with 10μM fenretinide (Figure 4). RS4;11 cells
display the greatest activation of executioner Caspase 3 (as
observed by loss of pro-Caspase) with fenretinide treatment.
Interestingly, activation of Caspase 9 (which mediates the
intrinsic/mitochondrial apoptotic pathway) was not very
pronounced in RS4;11 or REH cells and was not detected
in CCRF-CEM or MOLT4 cells (data not shown). As shown
in Figure 4, fenretinide activated Caspase 8 in the RS4;11
and CCRF-CEM cell lines (as observed by cleavage of
the Caspase) but not in MOLT4 cells. There was limited
activation of Caspase 8 in REH cells compared to RS4;11 and
CCRF-CEM cells. A dose of 10μM fenretinide is required
to observe some Caspase 8 cleavage in REH cells while
5μM drug results in near complete cleavage of the Caspase
in both RS4;11 and CCRF-CEM cells (Figure 4). However,
fenretinide-induced apoptosis in RS4;11 or CCRF-CEM
cells does not require either Caspase 8 or Caspase 9. As
shown in Figure 5, inhibition of Caspase 9 actually increased
sensitivity to fenretinide in both cell lines. While inhibition
of Caspase 8 did result in statistically signiﬁcant protection
from fenretinide in RS4;11 and CCRF-CEM cells (P =
.001 and P = .003, resp.), the protection accorded was
only partial indicating that Caspase 8 may be necessary but
not suﬃcient for fenretinide-induced apoptosis in these cell
lines. These results are similar to ﬁndings reported recently
fromtheReynoldsgroupthatdemonstratedthatfenretinide-
induced apoptosis in the T-ALL-derived cell line COG-LL-
317 involves a Caspase independent mechanism [18].
3.3. Fenretinide Induces Cleavage and Nuclear Translocation
of PKC δ and Suppression of MCL-1 Expression in Leukemia
Cells that Are Sensitive to the Drug. A number of signaling
pathways that may be activated by fenretinide have been
identiﬁed (e.g., JNK) [6, 8, 12–14]; however, a role for PKC
in fenretinide-induced apoptosis has yet to be established.
A role for PKC in fenretinide-induced apoptosis in head
and neck squamous carcinoma cells has been suggested but
an analysis of which PKC isoforms might participate was
not performed [6]. REH and RS4;11 cells were treated with
varying doses of fenretinide for 24 hours and then lysed for
Western blot analysis. As shown in Figure 6, fenretinide had
littleeﬀectontheclassicalPKCisoforms(i.e.,PKCα,PK CβI,
and PKC βII) in REH cells but the expression of each of these
was suppressed in RS4;11 cells. Fenretinide potently induced
cleavage of novel PKC isoforms PKC δ and PKC ε in RS4;11
cells and to a lesser extent in REH cells (Figure 4). While the
signiﬁcance of PKC ε cleavage is not clear, cleavage of PKC
δ has been implicated as a positive regulator of apoptosis
[33–36].CCRF-CEMandMOLT4cellsweresimilarlytreated
with fenretinide and expression of PKC α,P K Cδ,a n d
PKC ε was examined (Figure 7). As was the case for RS4;11
cells,fenretinidesuppressedPKC αexpressionandpromoted
cleavage of PKC δ in CCRF-CEM cells. While the drug
did suppress expression of PKC ε,n oc l e a v a g ep r o d u c t
was detected (Figure 5). As was the case for REH cells,
fenretinide treatment of MOLT4 cells had little eﬀect on
PKC α e x p r e s s i o na n do n l yp r o m o t e dP K Cδ cleavage with
higher concentrations. Considering that cleaved PKC δ has
been implicated as a positive regulator of apoptosis, it is
not surprising to ﬁnd that the leukemia cells that are more
sensitive to fenretinide (i.e., RS4;11 and CCRF-CEM cells)
exhibit greater production of cleaved PKC δ compared to
the leukemia cells that are more resistant (i.e., REH and
MOLT4). Nuclear translocation of PKC δ has been shown to
be an important event in apoptotic stress signaling pathways
involving the kinase [33–36]. To determine if fenretinide
promoted nuclear translocation of PKC δ, subcellular local-
ization of the kinase was examined by immunoﬂuorescence
microscopy in vehicle (0.1% DMSO) treated CCRF-CEM
cells and cells treated with 1 μM fenretinide for 24 hours. As
shown in Figure 8,P K Cδ is mainly found in the cytoplasm
and in association with centrosomes in cells treated with
vehicle. However, in cells treated with fenretinide, antibody
against PKC δ labels the nuclear region, and is not present
in the cytoplasm (Figure 8). PKC δ continues to localize to6 Journal of Signal Transduction
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Figure 4: Fenretinide promotes Caspase activity in leukemia cell lines. Western blot analysis was performed using antibody against PARP,
Caspase 3, Caspase 8, and Caspase 9 on total lysate (0.25 × 106 cell equivalents) from REH, RS4;11, MOLT4, and CCRF-CEM (CEM) cells
treatedwithvehicle(lanemarkedV;0.1%DMSO),1μMfenretinide(lanemarked1),5μMfenretinide(lanemarked5),or10μMfenretinide
(lane marked 10).
the centrosome in cells treated with fenretinide (Figure 8,
arrow). The promotion of PKC δ localization to the nucleus
is consistent with proapoptotic signaling described by others
[33–36].
A recent study from the Reynolds group suggests that
fenretinide suppresses expression of the antiapoptotic BCL2
family member MCL-1 in ALL cells [18]. Cleaved PKC δ
has been suggested to regulate the degradation of MCL-
1 during apoptosis in U.V. irradiated keratinocytes [38]. It
is not surprising that fenretinide sensitive cell lines RS4;11
and CCRF-CEM display reduced expression of MCL-1 with
concomitant cleavage of PKC δ when treated with higher
doses of the drug (Figures 6 and 7). Fenretinide had no eﬀect
on the protein expression of the other antiapoptotic BCL2
family members expressed in the REH and RS4;11 cells (i.e.,
BCL2 and BCL-XL; Figure 6). In the Reynolds group study,
JNK was implicated as regulating MCL-1 degradation by
observations made using CCRF-CEM cells [18]. As shown
in Figure 6, RS4;11 cells exhibit suppression of MCL-1
protein expression in response to fenretinide but do not
display signiﬁcant fenretinide-induced activation of JNK (as
indicated by phosphorylation of the kinase). In fact, both
JNK1 and JNK2 appear to be downregulated by fenretinide
in RS4;11 cells at higher concentrations (Figure 6). Thus at
least in RS4;11 cells, suppression of MCL-1 expression is
independent of JNK.
3.4. Fenretinide Regulates MCL-1 and BCL2 Gene Transcrip-
tion in the Leukemia Cells. To examine if suppression of
MCL-1 expression by fenretinide might be mediated by
a transcriptional mechanism, gene expression of MCL-1
as well as fellow antiapoptotic family member BCL2 wasJournal of Signal Transduction 7
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Figure 5: Caspase Inhibitors do not protect leukemia cell lines
from fenretinide-induced apoptosis. Apoptosis of human leukemia
derived RS4;11 and CCRF-CEM (CEM) cells treated with vehicle
(0.2% DMSO) or fenretinide (10μM 4-HPR) for 24 hours was
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represent the mean ± S.D. from three separate experiments.
Statistically signiﬁcant diﬀerences from cell viability in untreated
cells (standard t-test; P<. 05) are marked by “∗”.
assessed in cells treated with the drug. REH, MOLT4, CCRF-
CEM, and RS4;11 cells were treated with vehicle (0.1%
DMSO) or 10μM fenretinide for 6 hours or 24 hours. RNA
wasisolated andtranscription ofMCL-1andBCL2wasmea-
sured by real-time PCR (RT-PCR). Expression of 18S RNA
was also measured so expression of each gene is reported as
transcript per million copies of 18S. To control the eﬀect of
fenretinide on transcription overall, B2M was also measured
by RT-PCR. Fenretinide does appear to have diﬀerential
eﬀects on transcription overall among the various cell lines
as determined by the changes in the level of B2M. There
was a slight reduction of B2M transcript observed in MOLT4
and RS4;11 cells treated with fenretinide for 24 hours (∼15%
reduction each; Figure 9). However, fenretinide suppressed
B2M transcription by nearly 2-fold after 24 hours in REH
cells and by nearly 3-fold after 24 hours in CCRF-CEM cells.
As shown in Figure 9, fenretinide did not suppress MCL-
1 transcription by more than 20% in any of the cells after
24 hours. In fact, there was a slight (i.e., ∼35%) increase
in MCL-1 transcript in RS4;11 cells when treated with the
drug for 24 hours. Thus loss of transcript cannot account
for the suppression of MCL-1 protein by 10μM fenretinide
in these cells that was demonstrated in Figure 6. CCRF-
CEM cells, which also exhibit reduced MCL-1 protein in
response to the drug (see Figure 7), likewise do not exhibit
muchdecrease(i.e., ∼18%)inMCL-1transcription.Actually
relative to B2M transcription, there is a >2-fold increase in
MCL-1 transcript in the fenretinide treated CCRF-CEM cells
when compared to control. Fenretinide actually promoted
MCL-1 protein expression in the REH cells (Figure 6).
Interestingly, there was a >2-fold increase in MCL-1 gene
expression in REH cells treated with 10μM fenretinide for
6 hours compared to vehicle treated control cells (Figure 9).
It remains to be determined if fenretinide promotes MCL-
1 protein expression in REH cells by a transcriptional
mechanism. Also, it is possible that fenretinide regulates
MCL-1geneexpressionbyothermeanssuchasamechanism
involving a micro-RNA. Still, the data presented here suggest
that downregulation of MCL-1 in the fenretinide sensitive
cell lines (i.e., RS4;11 and CCRF-CEM) does not occur via
a transcriptional mechanism.
Interestingly, REH and RS4;11 cells treated with 10μM
fenretinide for 24 hours exhibited >3-fold reduction and
>8-fold reduction, respectively, in BCL2 gene expression
compared to vehicle control cells treated for 24 hours
(Figure 9). Fenretinide induced loss of PKC ε in these cells
(Figures 6 and 7). PKC ε has been implicated as a regulator
of BCL2 gene expression in hematopoietic cells [40]. Thus
fenretinide may regulate BCL2 gene expression via a PKC
ε-mediated mechanism. It should be noted that fenretinide
did not aﬀect BCL2 protein levels after 24 hours in either
REH or RS4;11; however, BCL2 protein has a relatively
long half life compared to MCL-1 [41]. Overexpression of
exogenous BCL2 in CCRF-CEM cells has been shown to
protectthe cellsfrom the cytotoxic eﬀectsof fenretinide [17].
The eﬀect of fenretinide to suppress BCL2 gene expression
thus may be key to the cell death mechanism as the
antiapoptotic protein interferes with fenretinide drug action
when BCL2 gene expression is regulated by an artiﬁcial
promoter (i.e., CMV promoter) [17] and thus not subject
to regulation by the drug. While this potential mechanism
needs to be investigated further, the ability of fenretinide to
suppress BCL2 expression would have positive beneﬁts in
antileukemia strategies that would utilize fenretinide.
3.5. The Antioxidant Vitamin C Prevents PKC δ Cleav-
age Induced by Fenretinide. A plausible mechanism how
fenretinide promotes PKC δ cleavage might involve ROS
activation of Caspase 3 since the protease mediates cleavage
of this PKC isoform [33–36]. Nuclear translocation of
PKC δ precedes Caspase 3 cleavage and indeed fenretinide
promotes PKC δ nuclear translocation (Figure 8). As shown
in Figure 4, Caspase 3 is potently activated and PARP cleaved
in RS4;11 and CCRF-CEM cells treated with fenretinide
even when cells are treated with 1μMd r u g .V i t a m i nC
was shown to eﬀectively protect the leukemia cells from
fenretinide-induced apoptosis likely via a mechanism that
suppresses ROS (Figure 3). If PKC δ participates in the death
process, it would be predicted that Vitamin C would prevent
fenretinide-induced cleavage of PKC δ. RS4;11 cells were
treated with vehicle (0.1% DMSO), 0.4M Vitamin C, 5μM
fenretinide, or a combination of Vitamin C and drug at the
speciﬁedconcentrationsfor24hours.Proteinexpressionwas
analyzed by Western analysis. Consistent with the protec-
tive eﬀects of Vitamin C against drug-induced apoptosis,
VitaminCblockedfenretinide-inducedactivationofCaspase
3 (i.e., inhibited pro-Caspase cleavage) and suppressed
cleavage of PARP in the RS4;11 cells (Figure 10). As shown in
Figure 10, the antioxidant was eﬀective at preventing PKC δ
cleavage in cells treated with fenretinide. This result supports
a mechanism where fenretinide promotes ROS formation to
activate Caspase 3 resulting in PKC δ cleavage.8 Journal of Signal Transduction
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Figure 6: Fenretinide promotes PKC δ cleavage and suppresses MCL-1 expression in RS4;11 cells. Western blot analysis was performed
using antibody against PKC α,P K CβI, PKC βII, PKC δ,P K Cε, p-JNK, JNK, BCL-XL, MCL-1, BCL2, and Tubulin on total lysate (0.25×106
cell equivalents) from REH and RS4;11 cells treated with vehicle (lane marked V; 0.1% DMSO), 1μM fenretinide (lane marked 1), 5μM
fenretinide (lane marked 5), or 10μM fenretinide (lane marked 10) for 24 hours.
3.6. In REH Cells, the PKC Agonist Bryostatin-1 Potenti-
ates Fenretinide-Induced Apoptosis and Suppresses PKC δ
Expression. It has been previously demonstrated that the
PKC agonist Bryostatin-1 protects REH cells from apoptosis
induced by a number of clinically relevant chemothera-
peutic drugs including etoposide, ara C, and adriamycin
[27]. The mechanism how Bryostatin-1 protects REH cells
from chemotherapeutic drugs involves, at least in part, the
activation of PKC α resulting in the phosphorylation of
BCL2 [27]. Bryostatin-1 mimics diacylglycerol (DAG) and
binds to the DAG binding site of PKC resulting in activation;
however, prolonged exposure to the drug can result in
downregulation of particular PKC isoforms likely due to
feedback mechanisms [42]. REH cells were treated withJournal of Signal Transduction 9
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Figure 8: PKC-δ translocates into the nucleus in response to fenretinide (4-HPR) treatment. CCRF-CEM cells were treated with either
vehicle (A-A
  )o r1μM 4-HPR (B-B
  ) for 24 hours and then sedimented onto poly L-lysine coated coverslips. Cells were stained with anti
α tubulin to label the microtubule network (A-B), and anti-PKC δ (A
 -B
 ). In the untreated cells, the PKC δ localizes to the cytoplasm and
is concentrated at the centrosome (A
 , arrow). In the treated cells, the PKC δ is concentrated in the nucleus, and also at the cytoplasm (B
 ,
arrow). Fluorescence optics Bar = 5μM.
vehicle (0.2% DMSO) or 10μM fenretinide for 24 hours.
W h e r ea p p r o p r i a t e ,c e l l sw e r ep r e t r e a t e dw i t h1 0 n M
Bryostatin-1 1 hour prior to addition of vehicle or fen-
retinide. Cell viability was determined by trypan blue
dye exclusion dye assay. As shown in Figure 11(a),1 0 μM
fenretinide kills roughly 20% of REH cells. While 10nM
Bryostatin-1 alone has no toxic eﬀect on the REH cells,
nearly half of cells treated with both 10nM Bryostatin-1 and
10μM fenretinide were killed after 24 hours (Figure 11(a)).
The increase in fenretinide-induced cell death in the REH
cells due to Bryostatin-1 was statistically signiﬁcant (P =
.0006). Thus while Bryoststain-1 protects REH cells from
chemotherapeutic drugs, the PKC agonist promotes cell
death in response to fenretinide. To determine if Bryostatin-
1 acted similarly on RS4;11 cells treated with fenretinide,
RS4;11 cells were treated with fenretinide in the absence or10 Journal of Signal Transduction
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Figure 9: Fenretinide does not inhibit transcription of MCL-1 in
leukemia cells. Real-Time-PCR was performed using cDNA derived
from cells treated with vehicle (0.1% DMSO) or cells treated with
10μM fenretinide (4-HPR) for 6 hours or 24 hours. Expression of
MCL-1,BCL2,andB2Mgenesarepresentedasrelativeto106 copies
of 18S RNA.
presence of 10nM Bryostatin-1. Since RS4;11 cells are much
more sensitive to fenretinide compared to REH cells (see
Figure 1), RS4;11 cells were treated with 1μM fenretinide.
Bryoststin-1actuallyprotectedRS4;11cellsfromfenretinide-
induced apoptosis. As shown in Figure 11(b),R S 4 ; 1 1c e l l s
pretreated with 10 nM Bryostatin-1 demonstrated a signif-
icant decrease in response to 1μM fenretinide after 24 hours
compared to cells treated with fenretinide alone (46% cell
death versus 33% cell death resp.; P = .02). Thus unlike REH
cells,Bryostatin-1canprotectRS4;11cellsfromthecytotoxic
eﬀects of fenretinide.
Diﬀerential eﬀects of Bryostatin-1 on PKC δ in REH
cells and RS4;11 cells may provide a possible explanation
for the diﬀerence in eﬀect of Bryostatin-1 on fenretinide-
induced apoptosis in the two cell lines. REH and RS4;11 cells
were treated with vehicle (0.2% DMSO), 10nM Bryostatin-
1, fenretinide, or a combination of Bryostatin-1 and drug
at the speciﬁed concentrations for 24 hours. REH cells were
treated with 10μM fenretinide and RS4;11 cells were treated
with 1μM fenretinide. Protein expression was analyzed by
Western analysis. Consistent with the protective eﬀects of
Bryostatin-1 against fenretinide-induced apoptosis in the
RS4;11 cells, the PKC agonist blocked fenretinide-induced
cleavage of both PKC δ and PKC ε (Figure 12). Bryostatin-
1 alone had no eﬀect on PKC ε in REH cells though it did
prevent fenretinide-induced cleavage of PKC ε (Figure 12).
Since Bryostatin-1 augments fenretinide-induced cell death
but blocks cleavage of PKC ε in REH cells, it is likely that
cleaved PKC ε is not critical in the death process. Meanwhile,
Bryostatin-1 potently suppressed PKC δ expression in REH
cells and there was a near complete inhibition of PKC δ in
REH cells treated with the combination of Bryostatin-1 and
fenretinide (Figure 12). This result suggests that loss of PKC
δ sensitizes REH cells to fenretinide-induced cell death.
3.7. Suppression of PKC δ Expression Promotes Fenretinide-
Induced Apoptosis in RS4;11 and CCRF-CEM Cells. To
determine if cleaved PKC δ was required for fenretinide-
induced apoptosis, expression of the kinase was suppressed
in CCRF-CEM cells by shRNA. The shRNA plasmids were
introduced into cells by lentiviral transduction. As shown in
Figure 13, shRNA targeting PKC δ resulted in signiﬁcant loss
of protein when compared to the cells transduced with the
negative control. Control shRNA CCRF-CEM cells and cells
expressing PKC δ shRNA were treated with vehicle (0.1%
DMSO) or with 1μM, 5μM, or 10μM fenretinide for 24
hours and cell death was measured by trypan blue dye exclu-
sion. As shown in Figure 14, CCRF-CEM cells expressing
PKC δ shRNA were more sensitive to fenretinide compared
to control (i.e., ∼60% cell death versus ∼36% cell death with
5μM drug, resp.). The increase in fenretinide-induced death
in the CCRF-CEM cells expressing PKC δ shRNA compared
to control cells was signiﬁcant at drug concentrations of
1μMa n d5μM( i . e . ,P = .03 and P = .002, resp.). As shown
in Figure 13, CCRF-CEM cells expressing PKC δ shRNA
displayed more complete PARP cleavage with higher doses
of fenretinide compared to control cells though there was
not an observed increase in Caspase 3 cleavage. CCRF-CEM
cells expressing PKC δ shRNA displayed a complete lossJournal of Signal Transduction 11
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Figure 10: The antioxidant Vitamin C blocks fenretinide-induced cleavage of PKC δ in RS4;11 cells. Western blot analysis was performed
using antibody against PKC α,P K CβI, PKC βII, PKC δ,P K Cε, p-JNK, JNK, BCL-XL, MCL-1, BCL2, and Tubulin on total lysate (0.25×106
cell equivalents) from RS4;11 cells treated with vehicle (0.2% DMSO), 0.4M Vitamin C (Vit C), 10μM fenretinide (4-HPR), or 10μM
fenretinide after a 2 hour pretreatment with 0.4M Vitamin C (Combo) for 24 hours.
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Figure 11: Bryostatin-1 protects RS4;11 but not REH cells from fenretinide-induced cell death. Cell death of human leukemia derived REH
cells (a) and RS4;11 cells (b) treated with vehicle (0.2% DMSO) or fenretinide (10μM 4-HPR) for 24 hours was examined by trypan blue
dye exclusion assay. Where appropriate, cells were pretreated for 2 hours with 10nM Bryostatin-1 (Bryo). Error bars represent the mean ±
S.D. from three separate experiments. Statistically signiﬁcant diﬀerences from cell viability in untreated cells (standard t-test; P<. 05) are
marked by “∗”.
of both full length and cleaved PKC δ when treated with
fenretinide (Figure 13). Suppression of PKC δ did lead to an
increase in basal ROS levels in CCRF-CEM cells. As shown
in Figure 15, cells with PKC δ shRNA exhibited a nearly 2
fold increase in ROS production compared to control (P <
.001).Theincreasedsensitivitytofenretinideinthecellswith
PKC δ shRNA is reminiscent of observations with REH cells
treated with a combination of Bryostatin-1 and fenretinide.
Bryostatin-1 in combination with fenretinide resulted in
complete loss of PKC δ in REH cells (Figure 12) and the PKC
agonist promoted sensitivity to fenretinide (Figure 11(a)).
These results suggest that the role for PKC δ in fenretinide-
induced cell death in the leukemia cells is complex.
4. Discussion
The ﬁndings of this study suggest that PKC δ may play an
importantroleinfenretinide-inducedapoptosisinlymphoid12 Journal of Signal Transduction
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Figure 12: Bryostatin-1 suppresses PKC δ expression in REH cells. Western blot analysis was performed using antibody against PKC δ,
PKC ε,a n dT u b u l i no nt o t a ll y s a t e( 0 .25 × 106 cell equivalents) from REH cells and RS4;11 cells treated with vehicle (0.2% DMSO), 10nM
Bryostatin-1 (Bryo), fenretinide 4-HPR), or fenretinide after a 2 hour pretreatment with 10nM Bryostatin-1 (Combo) for 24 hours. Due to
diﬀerences in sensitivity to the drug, 10μM fenretinide was used for REH cells and 1μM fenretinide was used for RS4;11 cells.
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Figure 13: Suppression of PKC δ promotes PARP cleavage in CCRF-CEM cells. Western blot analysis was performed using antibody against
PKC δ, Caspase 3, PARP, and Tubulin on total lysate (0.25 × 106 cell equivalents) from CCRF-CEM transfectant cells with control shRNA
or CCRF-CEM transfectant cells with PKC δ shRNA that were treated with vehicle (lane marked V; 0.1% DMSO), 1μM fenretinide (lane
marked 1), 5μM fenretinide (lane marked 5), or 10μM fenretinide (lane marked 10) for 24 hours.
leukemia cells. Previous studies have established that the
synthetic Vitamin A analog acts via diverse mechanisms
but a role for any particular PKC isoform has remained
elusive [1–6]. An understanding of how fenretinide kills
malignantcellsiscriticalsincethedrughaspromiseasbotha
chemotherapeutic agent and a chemoprevention agent [1, 2,
43]. Fenretinide is well tolerated by patients and has shown
promise for treating children with neuroblastoma [43–45].
The eﬀectiveness of fenretinide in killing ALL derived cells
while sparing nonmalignant lymphoid cells suggests that it
may be an eﬀective agent in the therapy of ALL, especially
as it is so well tolerated in children [5, 9, 10, 18, 45].
Furthermore, the ability of fenretinide to overcome ABT-737
resistance in ALL cell lines suggests that fenretinide may be
usefulincombinationwithBH3mimeticdrugslikeABT-737
[18].
Ar o l ef o rP K Cδ in fenretinide-induced apoptosis in the
leukemia cell lines seemed logical as many of the reported
eﬀects of the drug would be expected to impact PKC δ
mediated signaling (e.g., stimulation of ROS production,Journal of Signal Transduction 13
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Figure 14:SuppressionofPKCδ promotesfenretinide-inducedcell
death in CCRF-CEM cells. Cell death of CCRF-CEM transfectant
cells with control nonspeciﬁc (NS) shRNA and CCRF-CEM trans-
fectant cells with PKC δ (PKC delta) shRNA treated with vehicle
(0.1% DMSO) or fenretinide (4-HPR at 1μM, 5μMo r1 0μMd o s e )
for24hourswasexaminedbytrypanbluedyeexclusionassay.Error
bars represent the mean ± S.D. from three separate experiments.
Statistically signiﬁcant diﬀerences from cell viability in untreated
cells (standard t-test; P<. 05) are marked by “∗”.
stimulation of sphingolipid production, activation of JNK)
[6,8–10]. In the leukemia cells treatedwithfenretinide, there
was a positive correlation between drug-induced apoptosis,
drug-induced ROS production, and drug-induced PKC δ
cleavage (Figures 1, 2, 6,a n d7). Fenretinide was shown to
promote nuclear translocation of PKC δ (Figure 8)w h i c h
is an important event in apoptotic signaling involving the
kinase [33–36]. The antioxidant Vitamin C protected all the
leukemia cells from fenretinide-induced cell death (Figure 3)
and prevented cleavage of the kinase (Figure 10). These
ﬁndings would suggest that ROS might promote PKC δ
cleavage to initiate proapoptotic signaling. While this notion
might prove true, a recent study has suggested that PKC δ
regulates ROS production as primary ﬁbroblasts from PKC
δ knockout mice or mice expressing a dominant negative
mutant of PKC δ exhibit increased production of ROS in
response to UV irradiation [46]. Consistent with such a
notion, the suppression of PKC δ by shRNA in CCRF-
CEM cells promoted basal ROS production (Figure 15)
and sensitized the cells to fenretinide-induced apoptosis
(Figure 14). The ﬁndings that inhibition of ROS blocks PKC
δ cleavage (thus suppressing activation of prostress signaling
mediated by the kinase) while loss of PKC δ enhances ROS
productionsuggestthatPKCδ mayregulateROSandinturn,
ROS may regulate the kinase. Such a mechanism is not too
diﬀerent from the relationship between PKC δ and Caspase
3; the protease cleaves and activates PKC δ but the kinase in
turn activates Caspase 3 [33–36].
The production of sphingolipids has been shown to
be an important event in fenretinide-induced apoptosis
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Figure 15: Suppression of PKC δ promotes ROS generation in
CCRF-CEM. Generation of ROS in CCRF-CEM transfectant cells
with control nonspeciﬁc (NS) shRNA and CCRF-CEM transfectant
cellswithPKCδ (PKCdelta)shRNAwasexaminedusingFACSCAN
analysis of Carboxy-H2DCFDA stained cells. Error bars represent
the mean ± S.D. from three separate experiments. Statistically
signiﬁcantdiﬀerencesfromcellviabilityinuntreatedcells(standard
t-test; P<. 05) are marked by “∗”.
[1, 3, 9, 10]. PKC δ on the one hand has been shown
to be activated by the sphingolipid ceramide, and on
the other hand, promotes ceramide production [47, 48].
In response to etoposide, PKC δ is translocated to the
mitochondriaandpromotesceramideproductioninprostate
cancer cells [48]. The Maurer group recently demonstrated
that fenretinide promotes production of dihydroceramide
rather than ceramide [10]. Interestingly, whereas Bryostatin-
1p r o t e c t sR E Hc e l l sf r o me t o p o s i d e[ 27], the PKC agonist
promotescelldeathinresponsetofenretinide(Figure 11(a)).
While it was shown that activation of PKC α appears to
be critical in protection of the REH cells from etoposide
[27], Bryostatin-1 suppressed PKC δ expression (Figure 12),
and potentiated fenretinide-induced cell death in the REH
cells (Figure 11(a)). Perhaps the diﬀerences may be due
to diﬀerent eﬀects of ceramide and dihydroceramide on
PKC δ mediated signaling pathways and for that matter
pathways regulated by other PKC isoforms. However, a role
for dihydroceramide as a regulator of cell death is only
just emerging, so much work is needed to establish how
dihydroceramide might promote cell death. It will be helpful
to understand how PKC δ may regulate and be regulated by
dihydroceramide.14 Journal of Signal Transduction
PKC δ has been implicated as a positive regulator of
JNK, particularly during stress signaling leading to apop-
tosis [49]. Activation of JNK in CCRF-CEM cells leading
to MCL-1 degradation observed by Kang and colleagues
[18] could be the result of PKC δ activation of JNK.
However, the loss of MCL-1 observed in RS4;11 cells in
the present study occurs in the apparent absence of JNK
activation (Figure 6). The correlation between fenretinide-
induced PKC δ cleavage and loss of MCL-1 in the drug
sensitive RS4;11 and CCRF-CEM cells (Figures 6 and 7)i s
consistent with reports demonstrating that PKC δ cleavage
product phosphorylates MCL-1 resulting in its proteasomal
degradation[38].However,fenretinide-induceddegradation
of MCL-1 is not required for drug-induced apoptosis since
REH cells actually express increasingly higher amounts of
the antiapoptotic protein with higher concentrations of
fenretinide (Figure 6) but high concentrations of the drug
arestill toxic to thecells(Figure 1). Fenretinide (10μM) does
promote MCL-1 gene expression after 6 hours in REH cells
(Figure 9), so the increased expression of MCL-1 protein
may reﬂect an increase in gene expression. The cleaved
PKC δ produced in the REH cells may not be suﬃcient
to promote degradation of MCL-1. These ﬁndings would
suggest that PKC δ may not be as important in fenretinide-
induced apoptosis in the REH cells. Still, the ﬁnding that
Bryostatin-1 potently suppresses PKC δ expression and
potentiates fenretinide-induced cell death suggests that PKC
δ would suggest otherwise. Identiﬁcation of PKC δ targets
other than MCL-1 will provide a better understanding
of how the kinase regulates fenretinide-induced apoptosis.
One possible mechanism may involve regulation of ROS
production. While we may not fully understand how PKC
δ regulates fenretinide-mediated apoptosis in lymphoid
leukemia cells, it is clear that the kinase may be a useful
targetforoptimizingantileukemiastrategiesthatmakeuseof
fenretinide.
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